Serological Study of IgG and IgM Antibodies to Cytomegalovirus and Toxoplasma Infections in Pregnant Women in Zakho City, Kurdistan Region, Iraq

1. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39(12):1385-94. doi: 10.1016/j.ijpara.2009.04.003. [PubMed: 19433092]. ## 2. Das S, Ramachandran VG, Arora R. Cytomegalovirus and rubella infection in children and pregnant mothers--a hospital based study. J Commun Dis. 2007;39(2):113-7. [PubMed: 18338691]. ## 3. Maruyama Y, Sameshima H, Kamitomo M, Ibara S, Kaneko M, Ikenoue T, et al. Fetal manifestations and poor outcomes of congenital cytomegalovirus infections: possible candidates for intrauterine antiviral treatments. J Obstet Gynaecol Res. 2007;33(5):619-23. doi: 10.1111/j.1447- 0756.2007.00621.x. [PubMed: 17845318]. ## 4. Li Z, Yan C, Liu P, Yan R, Feng Z. Prevalence of serum antibodies to TORCH among women before pregnancy or in the early period of pregnancy in Beijing. Clin Chim Acta. 2009;403(1-2):212-5. doi: 10.1016/j.cca.2009.03.027. [PubMed: 19302994]. ## 5. Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ. 2013;91(7):501-8.doi: 10.2471/blt.12.111732. [PubMed: 23825877]. [PubMed Central: PMC3699792]. ## 6. Bénard A, Petersen E, Salamon R, Chêne G, Gilbert R, Salmi LR, et al. Survey of European programmes for the epidemiological surveillance of congenital toxoplasmosis. Euro Surveill. 2008;13(15):18834. doi: 10.2807/ese.13.15.18834-en. [PubMed: 18445459]. [PubMed Central: PMC2740836]. ## 7. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86-102. doi: 10.1128/CMR.00062-12. [PubMed: 23297260]. [PubMed Central: PMC3553672]. ## 8. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253-76. doi: 10.1002/rmv.535. [PubMed: 17579921]. ## 9. Al-Hareth Z1, Monem F, Abdel Megiud N. Is low birth weight a risk indicator for congenital cytomegalovirus infection? J Infect Dev Ctries. 2009;4(1):44-7. doi: 10.3855/jidc.539. [PubMed: 20130378]. ## 10. Turbadkar D, Mathur M, Rele M. Seroprevalence of torch infection in bad obstetric history. Indian J Med Microbiol. 2003;21(2):108-10. [PubMed: 17642992]. ## 11. Simgamsetty S, Yarlagadda P, Yenigalla BM, Myneni RB. Study of seroprevalance of Toxoplasma gondii, Rubella virus and Cytomegalovirus (ToRC) infections in antenatal women presented with bad obstetric history and comparative evaluation of Nanoplex ToRCH screen ELISA kit with VIDAS. Int J Res Med Sci. 2015;3(5):1203-8. doi: 10.5455/2320-6012.ijrms20150532. ## 12. Al-Saeed AT, Abdulmalek IY, Ismail HG. Study of torch outcome on pregnancy and fetus in women with bod in duhok province – kurdistan region -iraq. Journal University of Zakho. 2015;3(A):171-82. doi: 10.25271/2015.3.2.37. ## 13. Hussein N, Balatay AA. The Seroprevalence of Toxoplasma, Cytomegalovirus and Rubella Infections inWomen with Abortion in Kurdistan Region of Iraq: a Brief Report. Int J Infect. 2019;6(1):e86734. doi: 10.5812/iji.86734. ## 14. Rasti S, Ghasemi FS, Abdoli A, Piroozmand A, Mousavi SG, Fakhrie-Kashan Z. ToRCH “coinfections” are associated with increased risk of abortion in pregnant women. Congenit Anom (Kyoto). 2016;56(2):73-8. doi: 10.1111/cga.12138. [PubMed: 26499091]. ## 15. Vilibic-Cavlek T, Ljubin-Sternak S, Ban M, Kolaric B, Sviben M, Mlinaric-Galinovic G. Seroprevalence of TORCH infections in women of childbearing age in Croatia. J Matern Fetal Neonatal Med. 2011;24(2):280-3. doi: 10.3109/14767058.2010.485233. [PubMed: 20476874]. ## 16. Coêlho RA, Kobayashi M, Carvalho LB Jr. Prevalence of IgG antibodies specific to Toxoplasma gondii among blood donors in Recife, Northeast Brazil. Rev Inst Med Trop Sao Paulo. 2003;45(4):229- 31. doi: 10.1590/s0036-46652003000400011. [PubMed: 14502353]. ## 17. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011;121(5):1673-80. doi: 10.1172/JCI45449. [PubMed: 21659716]. [PubMed Central: PMC3083799]. ## 18. Sanoguet JM, Gómez JR. Creation and validation of the scale for measuring quality of life in patients with cancer: Puerto Rican version (ECVCA-PR). Bol Asoc Med P R. 2013;105(3):36-42. Spanish. ## 19. Revello MG1, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev. 2002;15(4):680-715. doi: 10.1128/cmr.15.4.680-715.2002. [PubMed: 12364375]. [PubMed Central: PMC126858]. ## 20. Josheghani SB, Moniri R, Taheri FB, Sadat S, Heidarzadeh Z. Prevalence of serum antibodies to TORCH infection in the first trimester of the pregnancy in Kashan, Iran. IJN. 2015;6(1):8-12. doi: 10.22038/ijn.2015.4149. ## 21. Arabzadeh AM, Mosavat SA, Eftekhari N. Seroepidemiology of Human Cytomegalovirus In Pregnant Women and their Neonates In Kerman City During 2005. Journal of Kerman University of Medical Sciences. 2007;14(4):279-88. Persian. ## 22. Pasman L. The complication of coinfection. Yale J Biol Med. 2012;85(1):127-32. [PubMed: 22461751]. [PubMed Central: PMC3313527]. ## 23. Abdoli A, Pirestani M. Are pregnant women with chronic helminth infections more susceptible to congenital infections? Front Immunol. 2014;5:53. doi: 10.3389/fimmu.2014.00053. [PubMed: 24575099]. [PubMed Central: PMC3921675]. ##